INTERNATIONAL MULTIDISCIPLINARY JOURNAL FOR
RESEARCH & DEVELOPMENT
SJIF 2019: 5.222 2020: 5.552 2021: 5.637 2022:5.479 2023:6.563 2024: 7,805
eISSN :2394-6334 https://www.ijmrd.in/index.php/imjrd Volume 12, issue 02 (2025)
414
INNOVATIONS IN THE TREATMENT OF INFLUENZA AND ARVI IN CHILDREN
UNDER ONE YEAR OF AGE
Solomonnik Oksana Nikolaevna
Department of infectious diseases Andijan State Medical Institute, Uzbekistan, Andijan
Relevance:
Acute respiratory viral infections (ARVI), including influenza, are among the most
common illnesses in early childhood, posing a significant risk for infants under one year of age.
Children in this age group have an immature immune system and limited physiological reserves,
making them more vulnerable to severe complications such as pneumonia, bronchiolitis, and in rare
cases, respiratory failure. Traditional antiviral therapies and supportive measures are often
constrained by age-related safety and efficacy issues. Therefore, exploring innovative treatment
methods is crucial to improving clinical outcomes, reducing hospitalization rates, and preventing
long-term sequelae in this high-risk population.
Keywords:
influenza, ARVI (acute respiratory viral infections), children under one year of age,
antiviral therapy, immunomodulation, prophylaxis, innovations in pediatrics.
Introduction
Infants under twelve months old represent a vulnerable demographic for influenza and other ARVI
pathogens (e.g., respiratory syncytial virus, parainfluenza, adenovirus). Their immune system’s
relative immaturity can lead to rapid progression of infection, complicating the clinical picture. Over
the last decade, substantial progress has been made in understanding viral pathogenesis, as well as in
developing novel therapies and preventive strategies [1, 2].
However, despite these advancements, several challenges persist:
Limited medication options
: Many antiviral drugs are not approved for use in infants under one
year, largely due to safety concerns and lack of robust clinical data.
Resistance development
: Influenza viruses and other respiratory viruses can mutate, diminishing
the effectiveness of existing antivirals.
Vaccination constraints
: The use of standard influenza vaccines in this age group is often limited
or contraindicated, and immunological responses may differ from those in older children or adults.
Objective of the article
: To review recent innovations in the treatment of influenza and ARVI in
children under one year of age, analyzing their efficacy and safety, and providing insight into the
future directions of pediatric antiviral therapy.
Materials and Methods
Literature Search and Inclusion Criteria
A comprehensive review of articles published in English from 2015 to 2025 was conducted using
medical databases such as PubMed, Scopus, and Web of Science.
Keywords included “influenza,” “ARVI,” “infants,” “antiviral therapy,” “innovations,” and
“pediatrics.”
Studies focusing on children under one year of age, including clinical trials, observational studies,
meta-analyses, and systematic reviews, were included.
Data Extraction
INTERNATIONAL MULTIDISCIPLINARY JOURNAL FOR
RESEARCH & DEVELOPMENT
SJIF 2019: 5.222 2020: 5.552 2021: 5.637 2022:5.479 2023:6.563 2024: 7,805
eISSN :2394-6334 https://www.ijmrd.in/index.php/imjrd Volume 12, issue 02 (2025)
415
Information on new antiviral agents (e.g., novel neuraminidase inhibitors, polymerase inhibitors like
baloxavir marboxil), immunomodulatory therapies, monoclonal antibodies, and adjunctive
treatments was extracted [3]. Safety profiles, dosage recommendations, and reported adverse effects
were carefully noted, especially regarding infants under one year [4]. Quality assessment of each
study was performed using standardized tools (e.g., GRADE for systematic reviews, CONSORT
checklist for clinical trials).
Analysis
Innovations in drug development, prophylactic measures, and supportive care strategies were
categorized and compared [5]. Emphasis was placed on real-world effectiveness, the feasibility of
large-scale implementation, and the potential impact on hospitalization rates [6]. A descriptive
synthesis of the data was performed, with subgroup analysis when possible (e.g., comparing
neonates under six months vs. older infants up to 12 months).
Results and Discussion
New Antiviral Agents
Recent years have seen the introduction of several novel antiviral drugs targeting influenza viruses:
Baloxavir Marboxil
: A polymerase inhibitor that has shown promise in treating uncomplicated
influenza in older pediatric populations and adults [7]. However, clinical data in infants under one
year remain limited. Preliminary findings suggest the possibility of dose adjustment for infants, but
further research is needed to confirm safety and efficacy [8].
Next-Generation Neuraminidase Inhibitors
: Studies indicate that extended-spectrum
neuraminidase inhibitors (e.g., peramivir) may reduce viral shedding in severe influenza.
Preliminary pediatric data, including compassionate use in children under one year, are encouraging,
with a low incidence of adverse events.
Monoclonal Antibodies and Immunomodulators
Monoclonal Antibodies (mAbs)
: The success of monoclonal antidiv prophylaxis for RSV (e.g.,
palivizumab, nirsevimab) has led to interest in developing influenza-specific mAbs. Some early-
phase trials have reported reduced influenza viral load and hospitalization rates in high-risk pediatric
groups [9]. These therapies may offer an alternative prophylactic strategy, especially for infants
ineligible for vaccination due to age or medical contraindications.
Immunomodulators
: Agents such as interferon-alpha nebulizers have been explored for infants,
demonstrating a potential reduction in ARVI duration and complications [10]. However, side effect
profiles, including irritability and local inflammation, necessitate cautious use and further research.
Innovations in Supportive Therapy
High-Flow Nasal Cannula (HFNC)
and Non-Invasive Ventilation: Technological advances have
improved respiratory support for infants with severe ARVI, reducing the need for invasive
mechanical ventilation and related complications (e.g., ventilator-associated pneumonia).
Nasal Irrigation with Novel Formulations
: Hypertonic saline solutions combined with mild
antiseptics have shown promise in reducing nasal congestion and improving airway patency, thereby
alleviating symptoms and potentially decreasing viral load in the upper respiratory tract.
Prophylactic Vaccination Strategies
INTERNATIONAL MULTIDISCIPLINARY JOURNAL FOR
RESEARCH & DEVELOPMENT
SJIF 2019: 5.222 2020: 5.552 2021: 5.637 2022:5.479 2023:6.563 2024: 7,805
eISSN :2394-6334 https://www.ijmrd.in/index.php/imjrd Volume 12, issue 02 (2025)
416
Maternal Immunization
: Vaccinating pregnant women against influenza has demonstrated a
protective antidiv transfer to the fetus [11]. This can offer partial immunity to infants in their first
months of life, although the level and duration of protection vary. Recent innovations in vaccine
formulations (e.g., adjuvanted vaccines) aim to enhance the immune response in the mother and
increase antidiv titers in neonates [12].
Passive Immunization with Hyperimmune Globulin
: Though not widely adopted, pilot studies in
neonates at high risk (e.g., premature infants) show promising data in preventing severe influenza
outcomes.
Challenges and Future Directions
Limited Clinical Data
: Regulatory restrictions and ethical considerations make large-scale clinical
trials challenging in this age group.
Cost-Effectiveness
: New therapies often have high production costs, potentially limiting
accessibility.
Personalized Medicine
: There is a growing interest in tailoring antiviral and immunomodulatory
treatments based on individual genetic and immunological profiles [13]. Overall, the results
underscore a trend toward targeted therapies and immunoprophylaxis, with a focus on minimizing
side effects while maximizing viral clearance and reducing complications [14].
Conclusion and Recommendations
Combination Therapies
: Integrating novel antivirals (e.g., baloxavir marboxil) with
immunomodulators or supportive care measures may enhance overall treatment efficacy for infants,
but safety profiles must be rigorously evaluated.
Monoclonal Antibodies
: Influenza-specific monoclonal antibodies show potential both for
prophylaxis and early treatment in high-risk infants. Further clinical trials are necessary to determine
optimal dosing regimens.
Maternal Immunization
: Strengthening programs to immunize pregnant women against influenza
remains a key preventative strategy, conferring partial immunity to neonates. Additional research is
needed to refine vaccine formulations for better passive protection.
Respiratory Support Innovations
: Widespread adoption of non-invasive ventilation techniques in
pediatric units can help reduce complication rates among infants with severe ARVI.
Large-Scale Studies
: Further multicenter, randomized controlled trials should focus on infants
under one year of age to establish clear guidelines for the safety and efficacy of new antiviral agents,
immunomodulators, and prophylactic interventions.
References
1.
World Health Organization.
Influenza (Seasonal)
. WHO; 2022. [
room/fact-sheets/detail/influenza-(seasonal)
]
2.
Yakubova, Ranohon Maksimovna. "CLINICAL COURSE OF VIRAL HEPATITIS B, C,
AND D IN PATIENTS WITH HEMATOLOGICAL PATHOLOGY." World of Scientific news in
Science 2, no. 3 (2024): 65-69.
3.
Nabijonovich, Kaxarov Abdukaxar. "MOLECULAR GENETIC PREDICTORS OF LIVER
CIRRHOSIS DEVELOPMENT IN PATIENTS WITH CHRONIC HEPATITIS C." Ethiopian
International Journal of Multidisciplinary Research 12, no. 02 (2025): 177-180.
INTERNATIONAL MULTIDISCIPLINARY JOURNAL FOR
RESEARCH & DEVELOPMENT
SJIF 2019: 5.222 2020: 5.552 2021: 5.637 2022:5.479 2023:6.563 2024: 7,805
eISSN :2394-6334 https://www.ijmrd.in/index.php/imjrd Volume 12, issue 02 (2025)
417
4.
Nabijonovich, Kaxarov Abdukaxar. "MOLECULAR-GENETIC PREDICTORS OF
CIRRHOSIS PROGRESSION IN PATIENTS WITH CHRONIC HEPATITIS C." Ethiopian
International Journal of Multidisciplinary Research 12, no. 02 (2025): 181-186.
5.
Gulamovich, Djurayev Muzaffar, and Kaxarov Abdukaxar Nabijonovich. "CHANGES IN
THE FUNCTIONAL STATE OF THE THYROID GLAND IN CHILDREN WITH BRONCHIAL
ASTHMA." International Multidisciplinary Journal for Research & Development 11, no. 01 (2024).
6.
Nikolaevna, S.O., ASSESSMENT OF INVASIVE AND NON-INVASIVE METHODS
FOR DIAGNOSIS OF HELICOBACTER INFECTION.
7.
Nikolaevna, S.O., 2024. ETIOLOGY, PATHOGENESIS AND TREATMENT OF MRSA
INFECTION. Ethiopian International Journal of Multidisciplinary Research, 11(10), pp.119-123.
8.
Nikolaevna, S.O., 2024. CLINIC OF THE INITIAL PERIOD OF SALMONELLASIS
CAUSED BY SALMONELLA TYPHIMURIUM IN CHILDREN. International Multidisciplinary
Journal for Research & Development, 11(01).
9.
Nikolaevna, Solomonnik Oksana. "ETIOLOGY, PATHOGENESIS AND TREATMENT
OF MRSA INFECTION." Ethiopian International Journal of Multidisciplinary Research 11, no. 10
(2024): 119-123.
10.
Zaynobidin ogli, S.M. and Sharifjonovich, A.N.M., 2023. CLINICAL AND
EPIDEMIOLOGICAL CHARACTERISTICS OF ACUTE INTESTINAL INFECTIONS IN
ANDIJAN REGION. International Multidisciplinary Journal for Research & Development, 10(12).
11.
Zaynobidin ogli, S.M., 2023. PREVENTION OF ACUTE RESPIRATORY VIRAL
INFECTIONS. International Multidisciplinary Journal for Research & Development, 10(12).
12.
Mirpozilovich, Yunusov Muzaffar. "HISTORY, DISTRIBUTION, AND PRESENT
STATUS OF AIDS." International Multidisciplinary Journal for Research & Development 11, no.
03 (2024).
13.
Mirpozilovich, Yunusov Muzaffar. "CARE OF PATIENTS WITH AIDS VIRUS AND
INFORMATION ABOUT THE AIDS VIRUS." International Multidisciplinary Journal for
Research & Development 10, no. 09 (2023): 145-150.
14.
American Academy of Pediatrics.
Red Book: 2021–2024 Report of the Committee on
Infectious Diseases.
Elk Grove Village, IL: American Academy of Pediatrics; 2021.
